• Lubna Kamani and Asma Abdul Razzak.
• Lubna Kamani, FCPS, MRCP, FRCP, SCE (Gastro) Professor & Director GI Residency Program Liaquat National Hospital Karachi, Pakistan.
• Pak J Med Sci. 2024 Jan 1; 40 (1Part-I): 227232227-232.

AbstractPregnant women and the general public are both directly impacted by cirrhosis which is a chronic liver disease. It is also widely known that women who have a history of injectable drug use and cirrhosis are more prone to experience unfavorable consequences that have a negative impact on the health of both the mother and the unborn child. Higher maternal Hepatitis-C Virus (HCV) in pregnancy viral load, length of labor, use of amniocentesis or fetal scalp monitoring and protracted membrane rupture are all the risk of perinatal transmission of HCV in newborns. Globally, a large number of childbearing-age women become affected by HCV every year and vertical transmission of HCV is still a serious public health concern. Pregnancy-related immune alterations have a significant impact on the course of HCV infection throughout the third trimester and provide favorable circumstances for the spread of the virus. The exacerbation of hepatic damage during pregnancy and the postpartum period is mostly responsible for HCV-specific cell-mediated immune responses. An extensive literature search done via electronic search engine including Cochrane library databases, PubMed, Google Scholar, Science Direct and HCV in pregnancy articles were included.Copyright: © Pakistan Journal of Medical Sciences.

5 keywords...

hide…